CN1290166A - 运动障碍的治疗 - Google Patents

运动障碍的治疗 Download PDF

Info

Publication number
CN1290166A
CN1290166A CN99802790A CN99802790A CN1290166A CN 1290166 A CN1290166 A CN 1290166A CN 99802790 A CN99802790 A CN 99802790A CN 99802790 A CN99802790 A CN 99802790A CN 1290166 A CN1290166 A CN 1290166A
Authority
CN
China
Prior art keywords
riluzole
levodopa
pharmaceutical composition
per day
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99802790A
Other languages
English (en)
Chinese (zh)
Inventor
E·梅拉迈德
R·德加德帝
I·齐夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/xx
Priority claimed from IL12710298A external-priority patent/IL127102A0/xx
Application filed by Mor Research Applications Ltd filed Critical Mor Research Applications Ltd
Publication of CN1290166A publication Critical patent/CN1290166A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN99802790A 1998-01-09 1999-01-05 运动障碍的治疗 Pending CN1290166A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL122883 1998-01-09
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
IL127102 1998-11-17

Publications (1)

Publication Number Publication Date
CN1290166A true CN1290166A (zh) 2001-04-04

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99802790A Pending CN1290166A (zh) 1998-01-09 1999-01-05 运动障碍的治疗

Country Status (10)

Country Link
EP (1) EP1043996A2 (enExample)
JP (1) JP2002500181A (enExample)
KR (1) KR20010033978A (enExample)
CN (1) CN1290166A (enExample)
AU (1) AU1780699A (enExample)
BR (1) BR9906821A (enExample)
CA (1) CA2317811A1 (enExample)
NO (1) NO20003529L (enExample)
PL (1) PL342098A1 (enExample)
WO (1) WO1999034785A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
AU3295900A (en) * 1999-03-12 2000-10-04 Aventis Pharma S.A. Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2809620B1 (fr) * 2000-06-05 2002-08-02 Aventis Pharma Sa Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Also Published As

Publication number Publication date
WO1999034785A3 (en) 1999-09-16
CA2317811A1 (en) 1999-07-15
EP1043996A2 (en) 2000-10-18
NO20003529L (no) 2000-09-08
BR9906821A (pt) 2000-10-17
NO20003529D0 (no) 2000-07-07
KR20010033978A (ko) 2001-04-25
WO1999034785A2 (en) 1999-07-15
JP2002500181A (ja) 2002-01-08
AU1780699A (en) 1999-07-26
PL342098A1 (en) 2001-05-21

Similar Documents

Publication Publication Date Title
Alexander et al. Prostaglandin analog treatment of glaucoma and ocular hypertension
Tolosa et al. Meige disease: striatal dopaminergic preponderance
CA2003524C (en) Treatment of obesity
EP1435943B1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug for treating dyskinesia
EP3368160B1 (en) Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
KR20070085838A (ko) 운동 장애의 치료 방법
EP1093369A2 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
WO2011019845A1 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
DE60315258T2 (de) Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
CN1290166A (zh) 运动障碍的治疗
DE3686520T2 (de) Verwendung von einigen alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur therapeutischen behandlung von ideopathischem oder induziertem parkinsonismus.
DE3940410A1 (de) Neue verwendung von nmda-rezeptor-antagonisten
CN1674907A (zh) 瑞波西汀在治疗热潮红中的用途
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
JP5175015B2 (ja) ジスキネジーの治療
US7576073B2 (en) Combined therapy for the treatment of parkinson's disease
WO2005041966A1 (en) Treatment of parkinson's disease using apomorphine in combination with an apomorphine prodrug
US5229394A (en) Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
Torri et al. (409) A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy
TW200418447A (en) New method for treating urinary disorders
Dimitriou et al. Buspirone vs alprazolam: a double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms
MXPA00006800A (en) Treatment of dyskinesias
CN1105560C (zh) 依法克生用于制备治疗亨廷顿舞蹈病的药物的应用
Suarez (408) Efficacy and Safety of Two Doses of a Fixed Dose Combination of Tramadol and Diclofenac in Acute Pain
ARIFULLA et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication